Notice: This company has been marked as potentially delisted and may not be actively trading. Theseus Pharmaceuticals (THRX) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period The True Cost of LayoffsAugust 9, 2024 | bloomberg.comKS2 / KS3 English: A Midsummer Night's Dream. 1: Welcome to AthensMay 20, 2024 | bbc.co.ukTheseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | finance.yahoo.comTheseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | prnewswire.comTrading was temporarily halted for "THRX" at 07:02 PM with a stated reason of "News pending."February 14, 2024 | marketbeat.comConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsJanuary 30, 2024 | finance.yahoo.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, THRX, GRCL, ROVRJanuary 20, 2024 | stockhouse.comShort Interest in Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) Drops By 37.4%Theseus Pharmaceuticals, Inc. (NASDAQ:THRX - Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 585,500 shares, a drop of 37.4% from the December 15th total of 936,000 shares. Based on an average daily volume of 690,600 shares, the short-interest ratio is presently 0.8 days. Currently, 3.8% of the company's shares are sold short.January 13, 2024 | marketbeat.comTHESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 31, 2023 | businesswire.comIs Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?December 29, 2023 | finance.yahoo.comTheseus Pharmaceuticals, Inc. (NASDAQ:THRX) Short Interest UpdateTheseus Pharmaceuticals, Inc. (NASDAQ:THRX - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 936,000 shares, a drop of 42.2% from the November 30th total of 1,620,000 shares. Based on an average daily volume of 620,000 shares, the short-interest ratio is presently 1.5 days. Currently, 6.1% of the company's shares are short sold.December 29, 2023 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONNDecember 27, 2023 | markets.businessinsider.comTheseus Pharmaceuticals Shares Rise 9.3% on Deal to Be Acquired by ConcentraDecember 22, 2023 | marketwatch.comConcentra Biosciences to Acquire Theseus Pharmaceuticals for $3.90 to $4.05/ShrDecember 22, 2023 | marketwatch.comTheseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In CashDecember 22, 2023 | markets.businessinsider.comTHRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to ShareholdersDecember 22, 2023 | tmcnet.comTheseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightDecember 22, 2023 | finance.yahoo.comUP Fintech, Cerence, Irsa Inversiones Y Representaciones among premarket gainers packNovember 27, 2023 | msn.comTheseus Pharma To Evaluate Expression Of Interest From Foresite, OrbiM And Proposal From ConcentraNovember 27, 2023 | markets.businessinsider.comTheseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCNovember 27, 2023 | finance.yahoo.comTheseus Pharmaceuticals Inc (THRX) Explores Strategic Alternatives Amidst Workforce ReductionNovember 14, 2023 | finance.yahoo.comTwo years after IPO, Theseus Pharmaceuticals lays off most its staff, explores saleNovember 14, 2023 | bizjournals.comThinking about buying stock in Theseus Pharmaceuticals, Vuzix, Jaguar Global Growth, Fisker, or Cardio Diagnostics Holdings?November 14, 2023 | benzinga.comTheseus Pharmaceuticals Shares Rise 35% on Workforce Reduction, Strategic Alternatives ConsiderationNovember 13, 2023 | marketwatch.comTheseus Pharmaceuticals explores strategic options; cuts workforce by 72%November 13, 2023 | msn.comTheseus Pharmaceuticals Announces Process to Explore Strategic AlternativesNovember 13, 2023 | finance.yahoo.comTrading was temporarily halted for "THRX" at 04:11 PM with a stated reason of "News pending."November 13, 2023 | marketbeat.comTheseus Pharmaceuticals Inc THRXNovember 7, 2023 | morningstar.comTheseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare ConferenceNovember 7, 2023 | finance.yahoo.comTheseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth PlansOctober 9, 2023 | finance.yahoo.comTheseus Pharmaceuticals: Picking Up The Pieces After A Lead FailureSeptember 29, 2023 | msn.comTheseus Pharmaceuticals, Inc. Expected to Earn Q3 2023 Earnings of ($0.37) Per Share (NASDAQ:THRX)Theseus Pharmaceuticals, Inc. (NASDAQ:THRX - Free Report) - Stock analysts at Wedbush boosted their Q3 2023 earnings estimates for shares of Theseus Pharmaceuticals in a report issued on Thursday, August 10th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings perAugust 14, 2023 | marketbeat.comDown -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)August 11, 2023 | finance.yahoo.comTheseus Pharmaceuticals, Inc. (NASDAQ:THRX) Expected to Post Q1 2024 Earnings of ($0.33) Per ShareTheseus Pharmaceuticals, Inc. (NASDAQ:THRX - Free Report) - Wedbush issued their Q1 2024 earnings estimates for Theseus Pharmaceuticals in a research report issued on Thursday, August 10th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.33) per share for thAugust 11, 2023 | marketbeat.comDeciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: AnalystAugust 10, 2023 | markets.businessinsider.comTheseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | finance.yahoo.comTheseus Pharmaceuticals Recent Insider ActivityJuly 21, 2023 | benzinga.comMassive Insider Trade At Theseus PharmaceuticalsJuly 20, 2023 | benzinga.comDirector of Theseus Pharmaceuticals Makes $1.46M BuyJuly 20, 2023 | benzinga.comAfter Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)July 18, 2023 | finance.yahoo.comThinking about buying stock in AMC Entertainment, Archer Aviation, Theseus Pharmaceuticals, Quantumscape, or Acumen Pharmaceuticals?July 17, 2023 | benzinga.comTheseus (THRX) Falls 72% on Decision to Discontinue GIST StudyJuly 17, 2023 | msn.comTheseus Pharma Shares Fall 71%, Company Halts Development of Tumor Drug THE-630 in Patients with GISTJuly 14, 2023 | marketwatch.comSetback For Theseus Pharmaceuticals: Analysts Cut Price Targets But Remain Bullish On StockJuly 14, 2023 | markets.businessinsider.comTheseus Pharmaceuticals (NASDAQ:THRX) Price Target Lowered to $7.00 at Cantor FitzgeraldCantor Fitzgerald dropped their target price on shares of Theseus Pharmaceuticals from $23.00 to $7.00 and set an "overweight" rating for the company in a research report on Friday.July 14, 2023 | marketbeat.comWhy Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving PremarketJuly 14, 2023 | msn.comTHRX Tanks after Pausing Trial of Lead Cancer CandidateJuly 14, 2023 | msn.comDose-Limiting Toxicities: Theseus Pharma Terminates THE-630 Study For Gastrointestinal CancerJuly 14, 2023 | markets.businessinsider.comAnalyst Expectations for Theseus Pharmaceuticals's FutureJuly 14, 2023 | markets.businessinsider.comTheseus Pharmaceuticals Terminates Development Of THE-630July 13, 2023 | markets.businessinsider.com Get Theseus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for THRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. THRX Media Mentions By Week THRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. THRX News Sentiment▼0.000.50▲Average Medical News Sentiment THRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. THRX Articles This Week▼00▲THRX Articles Average Week Get Theseus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for THRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BDTX News VERU News ACIU News LIAN News MRNS News PHXM News DRTSW News BCTXW News EFTRW News FBIOP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:THRX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theseus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theseus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
